Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc2206489 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Combination therapy involving azacitidine for acute myeloid leukemia patients ineligible for intensive chemotherapy.
Leuk Res
December 2024
Department of Hematology, Taixing People's Hospital Affiliated to Yangzhou University, Taixing, China; Institute of Hematology, affiliated hospital of Yangzhou University, Taixing, China. Electronic address:
Acute myeloid leukemia (AML) is a complex hematological malignancy predominantly affecting the elderly, with a median diagnosis age of 68 years. Despite advances in treatment, elderly AML patients face suboptimal survival outcomes, with an estimated 5-year survival rate below 20 %. Epigenetic dysregulation, notably DNA methylation, is a key factor in the progression of myelodysplastic syndromes (MDS) to AML.
View Article and Find Full Text PDFAcute myeloid leukemia management and research in 2025.
CA Cancer J Clin
December 2024
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Article Synopsis
A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS.
Expert Rev Hematol
November 2024
Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Article Synopsis
- It highlights the different treatment combinations available, including monotherapy and pairings like ivosidenib with azacitidine, while exploring their effectiveness and survival benefits.
- Lastly, it points out ongoing uncertainties in treatment choices and the need for more randomized trials to clarify the best approaches, especially after transplantation and in combination with other therapies.
Current status and research directions in acute myeloid leukemia.
Blood Cancer J
September 2024
From the Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.
Article Synopsis
- Advances in understanding the molecular pathobiology of acute myeloid leukemia (AML) have led to the development of twelve new targeted therapies approved since 2017, including various inhibitors and antibody-drug conjugates.
- These therapies, such as venetoclax and FLT3 inhibitors, aim to treat specific AML subsets and improve patient outcomes through precision medicine.
- Successful treatment of AML requires specialized expertise, access to diverse therapies, and a strong supportive care system, alongside ongoing research into new treatment options and combinations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!